arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Karyopharm Therapeutics Inc.

KPTI
$0.07 ▼ -0.02 (-21.45%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
44
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Karyopharm Therapeutics Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap —
Dividend Yield —
Revenue Growth -11.9% ↘
Op. Margin -67.4% ↗
ROIC 6.8% ↘
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$33.43M
↓ -11.9% —
Net Income Profit after all expenses
$-67.02M
↓ -79.9% —
Operating Margin Operating profit as % of sales
-67.4%
↑ +11.7% 4th
FCF / Share Free cash flow per share
$-0.38
↓ -128.3% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
4
Returns
98
Financial Health ↓
32
Cash Quality ↓
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 58 quarters